Microtubule

Human medicines European public assessment report (EPAR): Mevlyq, eribulin, Status: Opinion

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, European Commission, Breast, INN, Physician, ATC, Tubulin, EMA, International, Gesellschaft mit beschränkter Haftung, Civil service commission, Microtubule, Medication package insert, Committee, Patient, Anatomy, Eribulin, Medicine, CHMP, Pharmaceutical industry

Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.

Key Points: 
  • Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.
  • Since Mevlyq is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Halaven was not required.
  • Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
  • - Marketing authorisation applicant
    - YES Pharmaceutical Development Services GmbH
    - Opinion adopted
    - 14/12/2023
    - Opinion status
    - Positive

Nano-sized probes reveal how cellular structure responds to pressure

Retrieved on: 
Monday, November 20, 2023
The Journal, Map, Cell, Cell death, Mechanics, NIMS, System, Distortion, Diabetes, Cancer, Science, Splenic infarction, JSPS, Parkinson's disease, Skeleton, Feedback, Hospital, Microtubule, Advanced Materials, Machine learning, Camping, Microscope

A new technique allows researchers to map how the cellular 'skeleton' adapts to external stress.

Key Points: 
  • A new technique allows researchers to map how the cellular 'skeleton' adapts to external stress.
  • The method uses nanoscale probes, with tips just a few billionths of a metre in size, to measure and map how force gets distributed across the cellular surface and throughout the cell.
  • Hospitals currently use the size, shape, and structure of a cell in diagnosing cancer.
  • However, these features don't always provide enough information to tell the difference between healthy and diseased cells.

POLIVY (Polatuzumab Vedotin-piiq) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Biotechnology, General Health, Pharmaceutical, Health, MMAE, Apoptosis, Research, Immunoglobulin G, ADC, Clinical trial, SWOT, EU4, Microtubule, Polatuzumab vedotin, Roche, CD79B, Cell division, NHL, Fine chemical, Risk management, Vaccine, Pharmaceutical industry, DLBCL

This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about POLIVY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the POLIVY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to POLIVY for DLBCL?

Human medicines European public assessment report (EPAR): Mevlyq, eribulin, Status: Opinion

Retrieved on: 
Monday, December 18, 2023
Medicine, Anatomy, Breast, ATC, European Commission, Eribulin, International, INN, EMA, Civil service commission, Patient, Medication package insert, Marketing, CHMP, Microtubule, Committee, Medical Subject Headings, Tubulin, Physician, Gesellschaft mit beschränkter Haftung, Instrumentation, Vaccine, Pharmaceutical industry, Generic drug, Medical imaging, Medicinal plants, Liposarcoma

Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.

Key Points: 
  • Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.
  • Since Mevlyq is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Halaven was not required.
  • Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
  • - Marketing authorisation applicant
    - YES Pharmaceutical Development Services GmbH
    - Opinion adopted
    - 14/12/2023
    - Opinion status
    - Positive

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models

Retrieved on: 
Tuesday, October 31, 2023
Microtubule, GBM, AACR, Therapy, Cytoskeleton, Conference, Research, Cell, Glioblastoma, University of Toledo College of Medicine and Life Sciences, Disease, Neoplasm, Drug discovery, Recurrence, University, Patient, Medical imaging

Professor Eisenmann’s research interests include glioblastoma invasion programs and developing small molecule therapeutics that target cytoskeleton networks.

Key Points: 
  • Professor Eisenmann’s research interests include glioblastoma invasion programs and developing small molecule therapeutics that target cytoskeleton networks.
  • She has built a comprehensive glioblastoma patient cell line repository of more than 6 dozen samples of primary and therapy-resistant recurrent tumors.
  • The presentation demonstrated the monotherapy activity of plinabulin at 10-30 nM at killing 3D neurospheres from five glioblastoma multiforme (GBM) patient-derived primary cell lines and therapy-resistant cell lines.
  • Plinabulin had shown single agent activity in transgenic GBM animal model with survival benefit compared to placebo,” said Dr. Kathryn Eisenmann.

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Retrieved on: 
Tuesday, April 11, 2023
Microtubule, Infection, University of Rochester Medical Center, Human, Partnership, University, EEV, Marketing, Public, Mpox, COVID-19, African, Animal efficacy rule, CFR, Smallpox, Research, Cmax, Cavg, Associate, Development, Patient, Multiple organ dysfunction syndrome, Dentistry, Immunology, Viral, FDA, Death, BARDA, Virus, Pneumonia, Vaccine, Microbiology, Vaccinia

MIAMI, FL, April 11, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.

Key Points: 
  • These preclinical study results support the expansion of sabizabulin’s program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
  • The purpose of the study was to evaluate the mechanism of antiviral efficacy of sabizabulin, a novel microtubule disruptor, against the prototypical poxvirus vaccinia in cell culture.
  • To assess the ability of sabizabulin to slow or stop vaccinia virus cell-to-cell spread, BSC40 cells were treated with different concentrations of sabizabulin before inoculation with vaccinia virus at a low multiplicity of infection.
  • In this study, sabizabulin, by disrupting microtubules, was able to prevent the export and release of infectious vaccinia virus.

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference

Retrieved on: 
Tuesday, March 7, 2023
Trigger, Protein, Mitosis, Growth, Cell division, Reactive oxygen species, ROS, Cancer, Lung cancer, FDA, Poster, NLRP3, Therapy, RAS, Conference, AACR, NQO2, Microtubule, Patient, KRAS, JNK, Vaccine, Pharmaceutical industry

NEWTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced new preclinical data characterizing rigosertib’s mechanisms of action in a poster at the American Association for Cancer Research Special Conference on Targeting RAS (AACR Targeting RAS Conference).

Key Points: 
  • “The preclinical results presented at the Targeting RAS Conference increase our understanding of rigosertib’s anti-cancer effects and thereby represent a valuable tool to inform its continued clinical development,” said Mark Gelder, M.D., Chief Medical Officer of Onconova.
  • “I am particularly encouraged by data showing rigosertib-induced activation of the NLRP3 inflammasome.
  • Additional data identified the proteins NQO2, ERO1A, and NEK7 as potential novel targets that may be modulated by rigosertib.
  • Activation of NQO2 and/or ERO1A leads to reactive oxygen species (ROS)-induced activation of JNK signaling, which in-turn leads to RAS-MAPK pathway inhibition.

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics & Leadartis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Consumer, Health, Men, Clinical Trials, Oncology, Physical examination, Testicular cancer, News, Prednisone, Ageing, Tubulin, Survival rate, Prognosis, Route, Prostate cancer, Sanofi, European Medicines Agency, Complex, Microtubule, Cell cycle, II, Administration, BioNTech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cryptorchidism, Discovery, Epidemiology, Interphase, FDA, Cancer, SE, Knowledge, Carlos Roa, CLDN6, Route of administration, CAR, Risk, Metaphase, History, Food, Apoptosis, Therapy, Patient, RNA, Cabazitaxel, Clinical trial, EMA, Docetaxel, Dietary supplement, Vaccine, Pharmaceutical industry, Testicle

This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.

Key Points: 
  • This "Testicular Cancer - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Testicular Cancer pipeline landscape.
  • Testicular cancer is one of the most common malignancies in men aged 15 to 45 years.
  • Complex environmental and genetic factors are involved in the development of testicular cancer; common risk factors include cryptorchidism, family history of testicular cancer, personal history of testicular cancer in the contralateral testis, age, and ethnicity.
  • Testicular Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Regenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B Financing

Retrieved on: 
Wednesday, August 24, 2022
Health, Diabetes, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Nerve, Hypoesthesia, Spasm, Muscle, Safety, Technology, Pain, CIPN, Peripheral neuropathy, HDAC6, View, Therapy, Microtubule, Disease, Lists of diseases, Nutrient, Sensation, Board, Chemotherapy-induced peripheral neuropathy, Paralysis, Leukemia, Skin, SVP, Diabetes, Sickle cell disease, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., CMT, Paresthesia, HDAC, Secondary research, Patient, DPN, Pharmaceutical industry

Regenacy Pharmaceuticals Inc , a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced completion of enrollment of the companys phase 2 study of ricolinostat, an oral selective histone deacetylase 6 (HDAC6) inhibitor, in painful diabetic peripheral neuropathy (DPN).

Key Points: 
  • Regenacy Pharmaceuticals Inc , a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced completion of enrollment of the companys phase 2 study of ricolinostat, an oral selective histone deacetylase 6 (HDAC6) inhibitor, in painful diabetic peripheral neuropathy (DPN).
  • The ongoing double-blinded placebo-controlled clinical study, which recently completed enrollment, assesses the efficacy of ricolinostat in patients with painful DPN and other neuropathic symptoms.
  • Regenacy plans to use the additional financing from this Series B to continue advancing the ricolinostat clinical development program.
  • This Series B positions Regenacy for continued progress as we uncover the potential of ricolinostat to restore peripheral nerve function.

Molecular robots work cooperatively in swarms

Retrieved on: 
Wednesday, April 20, 2022
Veni, vidi, vici, NEDO, DNA, Robotics, Nagoya University, Scientific method, Research, New Energy and Industrial Technology Development Organization, Kansai University, Collection, Transport, Future, New energy, Associate, Kinesin, Columbia University, Ministry, Hokkaido University, Efficiency, Development, Science and technology, List, Environment, MEXT, Workload, Faculty, Culture, McMaster Faculty of Science, Microtubule, Kyushu University, Assistant, Medical device, Beekeeping, 3D printing, Sport, Technology, Science, Education

Swarm robotics is a new discipline, inspired by the cooperative behavior of living organisms, that focuses on the fabrication of robots and their utilization in swarms to accomplish complex tasks.

Key Points: 
  • Swarm robotics is a new discipline, inspired by the cooperative behavior of living organisms, that focuses on the fabrication of robots and their utilization in swarms to accomplish complex tasks.
  • Macro-scale swarm robots have been developed and employed for a variety of applications, such as transporting and accumulating cargo, forming shapes, and building complex structures.
  • However, the DNA and azobenzene used in the molecular machines and the cargo were different, so swarming could be controlled independently of cargo-loading.
  • "In the near future, we expect to see microrobot swarms used in drug delivery, contaminant collection, molecular power generation devices, and micro-detection devices," says Akira Kakugo.